KFA-027
KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections[1].
Product Specifications
UNSPSC
12352005
Target
HIV
Related Pathways
Anti-infection
Field of Research
Infection
Smiles
CC(C#CC1=NC([C@@H](NC(CN2N=C(C3=C2C(F)([C@H]4[C@@H]3C4)F)C(F)(F)F)=O)CC5=CC=CC=C5)=C(C=C1)C6=C7C(C(NS(C)(=O)=O)=NN7CC(F)(F)F)=C(C=C6)Cl)(S(C)(=O)=O)C
Molecular Formula
C39H34ClF8N7O5S2
Molecular Weight
932.30
References & Citations
[1]Adu-Ampratwum D, et al. Delineating Structural Functionalities of Lenacapavir Amenable to Modifications for Targeting Emerging Drug-Resistant HIV‑1 Capsid Variants. ACS Med Chem Lett. 2025 Sep 23;16 (10) :2007-2014.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400158-100 1x 100 µL
Cytokeratin 17 (E3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041073-500 1x 500 µL
HLA-Aw32 & HLA-A25 (MHC I) (CATA-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details